Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RUXIENCE vs BEYFORTUS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ruxience (rituximab) is a monoclonal antibody that binds to CD20 antigen on B-lymphocytes, initiating complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), leading to B-cell depletion.
BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) F protein, inhibiting viral entry into host cells by blocking the fusion of the viral envelope with the host cell membrane.
Non-Hodgkin lymphoma (NHL),Chronic lymphocytic leukemia (CLL),Rheumatoid arthritis (RA),Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA),Pemphigus vulgaris
Prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants entering their first RSV season, and in children up to 24 months of age who remain vulnerable through their second RSV season.
375 mg/m2 intravenous infusion once weekly for 4 weeks (for non-Hodgkin lymphoma); 375 mg/m2 intravenous infusion day 1 of each cycle for 6 cycles (in combination with CHOP); 500 mg fixed dose intravenous infusion on days 1 and 15 of cycle 1, then day 1 of cycles 2-6 (in combination with fludarabine and cyclophosphamide for CLL); 1000 mg intravenous infusion on days 1 and 15 (for rheumatoid arthritis, with or without methotrexate).
Not applicable; BEYFORTUS (nirsevimab) is indicated for prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants. No adult dose exists.
Mean terminal half-life: 18.0–22.0 days after last dose (range 7–32 days). Longer half-life with higher tumor burden and after multiple doses. Clinical context: maintains therapeutic levels for 3–6 months post-treatment.
Terminal elimination half-life is approximately 26.8 days in infants, supporting season-long protection after a single dose.
Rituximab is a monoclonal antibody; metabolism is via proteolytic degradation into small peptides and amino acids. No specific CYP450 enzyme involvement.
Nirsevimab is degraded via catabolic pathways into small peptides and amino acids.
Eliminated via reticuloendothelial system; no significant renal (less than 1%) or biliary/fecal excretion of intact rituximab. Target-mediated clearance via CD20 binding. Mean clearance: 0.14 L/h (initial), 0.012 L/h (after steady state).
Beyfortus (nirsevimab) is eliminated primarily via catabolism to small peptides and amino acids. No specific data on renal or biliary excretion; expected to undergo proteolytic degradation with minimal renal or fecal elimination of intact drug.
Specifically binds to CD20 antigen on B cells; no significant plasma protein binding (albumin or others). Almost exclusively bound to target cells.
Protein binding is approximately 99.5%, primarily to albumin.
Vd: 2.9–3.7 L (central compartment), 3.4–5.2 L (peripheral); approximates plasma volume (0.04–0.06 L/kg). Minimal extravascular distribution due to large molecular size.
Volume of distribution is approximately 4.5 L in infants (mean Vd ≈ 0.3 L/kg), indicating distribution primarily in plasma and interstitial fluid.
IV only; bioavailability 100% for IV infusion. No other routes available; subcutaneous formulation not applicable.
Bioavailability after intramuscular injection is approximately 70-80% (absolute bioavailability not established; relative to IV data).
No dose adjustment required for any degree of renal impairment. Ruxience has not been studied in patients with end-stage renal disease on dialysis.
No dosage adjustment required for renal impairment; nirsevimab is a monoclonal antibody not renally cleared.
No formal studies have been conducted in patients with hepatic impairment. No dose adjustment is recommended based on limited data.
No dosage adjustment required for hepatic impairment; nirsevimab is a monoclonal antibody not hepatically metabolized.
Safety and effectiveness in pediatric patients have not been established for most indications. For pediatric patients with certain conditions (e.g., nephrotic syndrome), dosing is based on BSA: 375 mg/m2 intravenous infusion weekly for 4 doses, with premedication.
Neonates and infants weighing <5 kg: 50 mg intramuscular (IM) single dose; infants weighing ≥5 kg: 100 mg IM single dose. Administer during RSV season.
No specific dose adjustment is recommended for elderly patients. However, monitor for infusion-related reactions, cardiac events, and infections more frequently due to age-related risk factors. Elderly patients may have slower clearance, but dose adjustments are not required based on pharmacokinetic data.
Not indicated for geriatric population; no dosing recommendations available.
Fatal infusion-related reactions, severe mucocutaneous reactions, progressive multifocal leukoencephalopathy (PML), and hepatitis B reactivation with fulminant hepatitis. Do not administer to patients with active hepatitis B infection.
No black box warning.
Infusion reactions, tumor lysis syndrome, severe mucocutaneous reactions (e.g., Stevens-Johnson syndrome), hepatitis B reactivation, PML, bowel obstruction and perforation, immunosuppression/infections, cardiac arrhythmias, renal toxicity (when used with cisplatin), and live vaccine administration risk.
Hypersensitivity reactions including anaphylaxis have been reported.,Use caution in patients with thrombocytopenia or any coagulation disorder due to risk of bleeding from intramuscular injection.
Active infection (especially hepatitis B), severe immunocompromised state, known hypersensitivity to rituximab or murine proteins, and live vaccine administration (contraindicated during and after therapy).
History of serious hypersensitivity reaction to nirsevimab or any component of the formulation.
No specific food interactions reported. Maintain adequate hydration to reduce risk of tumor lysis syndrome. Avoid grapefruit and other CYP3A4 modulators only if taking concomitant drugs metabolized by CYP3A4.
No known food interactions. BEYFORTUS is administered by intramuscular injection and does not interact with dietary components.
Rituximab is a humanized monoclonal antibody (Ig G1) that crosses the placenta, with fetal levels increasing during the second and third trimesters. Exposure in the first trimester is not associated with major malformations; however, second and third trimester exposure can cause B-cell depletion and lymphopenia in the neonate. Cases of severe neonatal agranulocytosis, including neutropenia, thrombocytopenia, and anemia, have been reported. Infant vaccination with live vaccines should be delayed until B-cell recovery. Overall, use during pregnancy is not recommended unless clearly needed.
BEYFORTUS (nirsevimab) is a human monoclonal antibody against respiratory syncytial virus. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental effects were observed in pregnant rabbits or cynomolgus monkeys at doses up to 10 times the human clinical exposure. However, because monoclonal antibodies are transported across the placenta in increasing amounts as pregnancy progresses (especially in the third trimester), potential fetal exposure may occur. Based on limited data, the risk of major birth defects and miscarriage is unknown but expected to be low due to the Ig G1 nature and lack of known teratogenic signal.
Rituximab is excreted into human breast milk in low amounts. The milk-to-plasma (M/P) ratio is approximately 0.003. Due to its large molecular weight and low oral bioavailability, systemic absorption in the nursing infant is minimal. However, limited data prevent full safety assessment; caution is advised, and breastfeeding is generally discouraged during therapy and for at least 6 months after last dose.
There are no data on the presence of nirsevimab in human milk, effects on the breastfed infant, or effects on milk production. Nirsevimab is a human monoclonal antibody (Ig G1) and is expected to be excreted into human milk in small amounts due to the high molecular weight and limited transfer via the neonatal Fc receptor. The M/P ratio has not been determined. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BEYFORTUS and any potential adverse effects on the breastfed infant from the drug or underlying condition.
No specific dose adjustments are recommended for pregnancy due to limited pharmacokinetic data. However, rituximab's clearance may increase in pregnancy due to expanded plasma volume, but the extent is unknown. Use lowest effective dose if absolutely necessary; consider delaying therapy until postpartum if possible.
No dosing adjustments are required for BEYFORTUS during pregnancy. Pregnancy-related physiological changes (e.g., increased plasma volume, altered renal clearance) are not expected to significantly affect the pharmacokinetics of a monoclonal antibody administered intramuscularly, as nirsevimab has a long half-life and is not renally excreted. The standard single dose of 50 mg (for infants <5 kg) or 100 mg (for infants ≥5 kg) is recommended regardless of pregnancy status.
Ruxience (rituximab) is a monoclonal antibody targeting CD20. Premedicate with acetaminophen, diphenhydramine, and methylprednisolone to reduce infusion reactions. Monitor for tumor lysis syndrome in high-tumor-burden patients. Hepatitis B reactivation risk requires screening and prophylaxis. Do not administer live vaccines during or after treatment until B-cell recovery.
BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It is administered as a single intramuscular injection, typically 50 mg for infants <5 kg and 100 mg for infants ≥5 kg. It is not a treatment for active RSV infection. It does not interfere with live attenuated vaccines; however, administration with other injectable vaccines at different sites is acceptable. Do not administer to infants with a history of severe hypersensitivity to nirsevimab or any excipients. Efficacy has not been established in infants with a history of RSV infection.
Inform your healthcare provider if you have any signs of infection, such as fever, chills, or sore throat.,Report any symptoms of infusion reactions, including itching, rash, difficulty breathing, or dizziness during or after infusion.,Avoid live vaccines (e.g., MMR, nasal flu, shingles) during treatment and for at least 6 months after last dose.,Use effective contraception during and for 12 months after treatment due to potential harm to fetus.,Notify your doctor if you have a history of hepatitis B, heart problems, or lung disease.,Expect that blood counts may drop; report unusual bruising, bleeding, or fatigue.
This vaccine is given as a single shot to prevent serious RSV disease in your infant.,It is not a treatment for active RSV infection; if your infant has RSV symptoms, inform the healthcare provider.,Common side effects include injection site reactions, rash, and fever. Contact your provider if these persist or worsen.,Inform the healthcare provider of any allergic reactions or bleeding disorders before administration.,Your infant can still receive other vaccines as scheduled.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RUXIENCE vs BEYFORTUS, answered by our medical review team.
RUXIENCE is a Monoclonal Antibody that works by Ruxience (rituximab) is a monoclonal antibody that binds to CD20 antigen on B-lymphocytes, initiating complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), leading to B-cell depletion.. BEYFORTUS is a Monoclonal Antibody for RSV Prophylaxis that works by BEYFORTUS (nirsevimab) is a recombinant human monoclonal antibody that binds to the prefusion conformation of the respiratory syncytial virus (RSV) F protein, inhibiting viral entry into host cells by blocking the fusion of the viral envelope with the host cell membrane.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RUXIENCE and BEYFORTUS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RUXIENCE is: 375 mg/m2 intravenous infusion once weekly for 4 weeks (for non-Hodgkin lymphoma); 375 mg/m2 intravenous infusion day 1 of each cycle for 6 cycles (in combination with CHOP); 500 mg fixed dose intravenous infusion on days 1 and 15 of cycle 1, then day 1 of cycles 2-6 (in combination with fludarabine and cyclophosphamide for CLL); 1000 mg intravenous infusion on days 1 and 15 (for rheumatoid arthritis, with or without methotrexate).. The standard adult dose of BEYFORTUS is: Not applicable; BEYFORTUS (nirsevimab) is indicated for prevention of respiratory syncytial virus lower respiratory tract disease in neonates and infants. No adult dose exists.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RUXIENCE and BEYFORTUS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RUXIENCE is classified as Category C. Rituximab is a humanized monoclonal antibody (IgG1) that crosses the placenta, with fetal levels increasing during the second and third trimesters. Exposure in the first trimester . BEYFORTUS is classified as Category C. BEYFORTUS (nirsevimab) is a human monoclonal antibody against respiratory syncytial virus. There are no adequate and well-controlled studies in pregnant women. In animal reproducti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.